AVI Biopharma, has formed a collaboration with leading scientists at the Karolinska Institute in Sweden to find new treatments for extensively drug resistant forms of tuberculosis known as XDR-TB. Funding and research support is provided by both parties, and intellectual property resulting from the work will be jointly owned, AVI said in a statement. AVI retains an exclusive right to acquire Karolinska's interest in intellectual property, AVI said.
http://www.seattlepi.com/xconomy/432791_xconomy117743.html
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment